RxDoctor Payments Data

John Oubre, MD

Internal Medicine · Covington, LANPI 1295945434

Payments from drug & device makers

$1,490in general payments, 2019–2025

Across 35 payments — averaging $42.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$497
  • Amgen$223
  • Inspire Medical Systems, Inc.$178
  • Tris Pharma Inc$125
  • Intuitive Surgical$100
  • Exact Sciences$88
  • plus $279 from 8 others

What the payments were for

  • Food & beverage$1,490100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,490 in reported general payments places this provider in the 70th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$64,952
Medicare patients
300
Services billed
1,143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide200$242,859
JardianceEmpagliflozin112$133,795
JanuviaSitagliptin Phosphate89$103,401
EliquisApixaban106$103,041
MounjaroTirzepatide65$97,136
FarxigaDapagliflozin Propanediol75$85,857
LinzessLinaclotide60$60,548
TrulicityDulaglutide34$50,927
XifaxanRifaximin11$34,088
XareltoRivaroxaban25$20,607
MyrbetriqMirabegron17$14,370
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$11,220
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,024
CreonLipase/Protease/Amylase11$9,285
GemtesaVibegron17$8,066

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$497$242,859200 claims
Lilly USA, LLCMounjaro, Trulicity$23$148,06399 claims
PfizerEliquis$86$103,041106 claims
AstraZenecaFarxiga, Symbicort$42$93,85593 claims
Johnson & JohnsonXarelto$14$20,60725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →